(Q44397776)

2 December 2017

title

The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP). (English)

1 reference

2 December 2017

1 reference

4

1 reference

2 December 2017

Juris J Meier

1

1 reference

2 December 2017

Baptist Gallwitz

2

1 reference

2 December 2017

Nina Siepmann

3

1 reference

2 December 2017

Carolyn F Deacon

5

1 reference

2 December 2017

Wolfgang E Schmidt

6

1 reference

2 December 2017

Michael A Nauck

7

1 reference

2 December 2017

publication date

1 May 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

113

1 reference

2 December 2017

issue

1-3

1 reference

2 December 2017

page(s)

95-100

1 reference

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

The incretin concept today

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

New developments in the incretin concept

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Immunoreactive gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

The hepatic extraction of gastric inhibitory polypeptide and insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900297-5

7 January 2021

10.1016/S0167-0115(02)00297-5

Identifiers

DOI

1 reference

release_mkel3epl3nguxim643eq6jgcoi

2 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mkel3epl3nguxim643eq6jgcoi

24 November 2022

mapped directly with Wikidata item

1 reference